Quickly and simply detection for coronaviruses including SARS-CoV-2 on the mobile Real-Time PCR without treating RNA in advance

Masaaki Muraoka[1,2]*, Yukiko Tanoi[1], Tetsutaro Tada[1], Mikio Mizukoshi[2],

Osamu Kawaguchi[1]

[1]Business Innovation Center, Nippon Sheet Glass Co. Ltd., 5-8-1, Nishi-Hashimoto, Midori-ku, Sagamihara-shi, Kanagawa, Japan

[2]Certified Non-Profit Organization Biomedical Science Association, 2-20-8, Kamiosaki, Shinagawa-ku, Tokyo, Japan

*Correspondence: masaaki.muraoka@nsg.com

Running Title; Real-time direct RT-PCR for SARS-CoV-2

Keyword; SARS-CoV-2, coronavirus, real-time RT-PCR, direct RT-PCR, quickly, rapidly, simply, easily, mobile, RNA virus

ABSTRACT

SARS-CoV-2 was reported to the WHO as an outbreak in Wuhan City, China on end of 2019, afterwards pandemic on the worldwide in 2020. The SARS-CoV-2 virus is less deadly, but far more transmissible. Therefore, it needs to detect and monitor quickly and simply on site to prevent SARS-CoV-2.

If detecting coronaviruses including SARS-CoV-2, the real-time RT-PCR method is sensitive and specific for the unique target, however, it must take long time and labour that RNA is treated in advance, transcribed and amplified. Therefore, referenced previously report, in this study, we modified various methods to prove hypotheses the followed.

Firstly, we hypothesized that real-time RT-PCR could be finished in very short time by the mobile real-time PCR device and one-step RT-PCR reagent. Secondly, we hypothesized that it was possible to perform RT-PCR utilizing the reagent as the above without RNA treatment in advance so called "direct".

Firstly, it was able to detect the positive control RNA of SARS-CoV-2 for less than 13.5 minutes by primer-probe referring to the CDC. Moreover, each detection value varied in accordance with each concentration (This correlation coefficient $R^2 > 0.95$). Secondary, it was possible to detect human coronavirus 229E with direct RT-PCR. Furthermore, each detection value varied in accordance with each titer ($TCID_{50}$ / mL) of human coronavirus 229E (This correlation coefficient $R^2 > 0.95$).

Considering the above, causing by utilizing the mobile real-time PCR device and the one-step real-time PCR reagent simultaneously following as: 1) It was possible to detect SARS-CoV-2 in very short time as compared to conventional method; 2) It was possible to detect human coronavirus quickly and simply with "direct". For these reasons, we hypothesized that it is possible to detect SARS-CoV-2 quickly and simply by utilizing methods the above without treating RNA in advance. This hypothesis is our next try.

STRENGTHS AND LIMITATIONS OF THIS STUDY

* This study developed it possible to detect the positive control RNA of SARS-CoV-2 more quickly than previously, however couldn't try to detect the genetic RNA.

* This study proved clearly that the human coronavirus instead of SARS-CoV-2 could be detected simply without treating RNA in advance by the same method above.

* This study couldn't try to utilize the human specimens because of our institution limited.

* This study could utilize the device and the reagents commercial and not especial.

INTRODUCTION

Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a cause of coronavirus disease 2019 (COVID-19) outbreak, of which the World Health Organization (WHO) declared pandemic on March 11, 2020 [1]. COVID-19 was firstly reported to the WHO as an outbreak in Wuhan City, Hubei Province, China on December 31, 2019, afterwards has rapidly spreading [2]. SARS-CoV-2 included, human infectious coronaviruses have been known seven types. Four of the seven types (HCoV-229E, HCoV-HKU1, HCoV-OC43, and HCoV-NL63) are included among the known causes of common cold. Whereas, other three human coronaviruses (the Middle East respiratory syndrome coronavirus [MERS-CoV], SARS-CoV, SARS-CoV-2) are highly pathogenic and can cause severe diseases presented as acute respiratory distress syndrome (ARDS) characterized by dysfunctional immune responses and severe pulmonary injury [3, 4]. The SARS-CoV-2 virus is genetically closely related to SARS-CoV, but which is less deadly and far more transmissible than MERS-CoV or SARS-CoV [5]. Therefore, it has been needed with rapidity and on site to detect and monitor.

The conventional method of confirmation for SARS-CoV-2 is based on detection of sequences unique in the virus RNA by nucleic acid amplification tests (NAAT) such as real-time reverse-

transcription polymerase chain reaction (RT-PCR). The viral genes targeted so far include the

nucleocapsid (N), envelop (E), RNA-dependent RNA polymerase (RdRP), spike (S), and open

reading frame 1 a/b (Orf1a/b), each of which primer and probe is various sequences [6, 7, 8, 9,

10, 11]. We recognize that the performance characteristics of PCR methods can vary with

reagents, PCR programs, and devices. Therefore, if devices or reagents changed, with simpler

and faster, it might be possible to detect.

Further, in quantitative RT-PCR, RNA extraction is required, followed by transcription,

amplification and detection. Current RT-PCR typically require more than 60 minutes for RNA

extraction, concentration and purification, and a further 90 minutes for transcription and

amplification [12]. It is difficult to handle RNA not to be damaged and lost, possible to infect

secondary and needed long time to detect. This might be due to the delay of the initial

introduction of RT-PCR detection for SARS-CoV-2 in various places.

As already reported rapid detection of SARS-CoV-2 with using mobile real-time PCR device

PCR1100 [10], we suggest "simpler and faster" method of RT-PCR in this paper as follows.

MATERIALS AND METHODS

Primer and Probe

93 Based on previously reported protocols of NIID [6, 7] and CDC [8, 9], and detection of

94 HCoV-229E [13], PCR primers and probes for real-time RT-PCR detection were selected to

95 target each N gene, and synthesised (Fasmac Co. Ltd., Japan) (Table 1).

Sample

Positive control RNA for SARS-CoV-2 against NIID version was kindly provided from

NIID (for N primer probe Ver.2 and N2 primer probe Ver.2 / Ver.3), and against CDC version

were synthesised (Fasmac Co. Ltd., Japan) based on each primer sequence and information

of GenBank: MN997409.1 (Table 2).

Each positive control RNA was applied 10-fold serial dilution with 10mM Tris-HCl (pH8.0

adjusted from 1M [Nippon Gene Co. Ltd., Japan] with water [UltraPure™ DNase / RNase-

Free Distilled Water, Thermo Fisher Scientific Inc., USA]) included 10μg / mL carrier RNA

(Ribonucleic acid from baker's yeast, Merck KGaA, Germany). Further, each concentration

of positive control RNA was assessed relatively with detection value of PCR1100.

The above, exposure to HCoV-229E is low-risk for healthy adults. The HCoV-229E virus

is easily accessible for the biosafety level 2 (BSL2) laboratory. Therefore, HCoV-229E may

be a good initial model for the evaluation against other coronaviruses, such as SARS-COV-

2, the coronavirus that causes COVID-19 [14]. There we substituted HCoV-229E for SARS-

2-CoV in direct RT-PCR. Human coronavirus 229E (HCoV-229E, VR-740™) was bought

by certified non-profit organization biomedical science association in Japan (BMSA) from

American Type Culture Collection (ATCC®, USA), afterwards, in cooperation of BMSA, it

was able to be used. Because to proliferate HCoV-229E, it was infected with MRC-5 cells

(CCL-171™, ATCC®), and cultured with EMEM medium (30-2003™, ATCC®) included

2% FBS (30-2020™, ATCC®) for 5~8 days in 5% CO2 at 35 °C. When virus titer was grown

up 8.9 x 10^6 Median tissue culture infectious dose (TCID$_{50}$ / mL), only that supernatant

without MRC-5 cells was stored at -80 °C before the assay. The supernatant included HCoV-

229E was thawed in the assay, not treated in advance and used with crude as it was. To assess

detection value of PCR1100 relative with titer of virus, the crude sample was applied 10-fold

serial dilution with 10mM Tris-HCl (pH8.0, the above).

Real-time RT-PCR

RT and PCR were carrying out in the one-step with using mobile real-time PCR device

PCR1100 for all tests of this study. Briefly describe the composition of RT-PCR reagent, 1 μL

of a sample (the crude or positive control RNA) was amplified in a 17 μL reaction solution

containing 1x Reaction Buffer, 0.25 μL of RT Enzyme Mix, 1.0 μL of DNA Polymerase

(THUNDERBIRD® Probe One-step qRT-PCR Kit, TOYOBO Co. Ltd., Japan), each final

concentration of primer and probe for target detection (Table 2). With preliminary tested, each

composition optimized (data not shown).

The RT-PCR conditions applied in this study were programmed as follows: RT incubation

and enzyme activation were serially performed at 50 °C for 150 seconds, at 95 °C for 15

seconds respectively. Afterwards, for SARS-CoV-2 against NIID version: thermal cycling was

then performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 16 seconds (annealing

and amplification) for fifty cycles. For SARS-CoV-2 against CDC version: thermal cycling

was then performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 7 seconds

(annealing and amplification) for fifty cycles. For HCoV-229E: thermal cycling was then

performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 8 seconds (annealing and

amplification) for fifty cycles. With preliminary tested, each condition was optimized (data

not shown).

Incidentally, the procedure of PCR1100 was according to previously reported [15].

RESULTS

Detection of SARS-CoV-2 in positive control RNA

In NIID version, both No.1 and No.2 could be simultaneously detected with multichannel

(Fig 1). As the result previously reported [7], No.2 was detected more sensitive than No.1,

possible to determine 10 copies too. Each Ct value (detected on the PCR1100) was depended

on the rate of dilution (No.1:$R^2 = 0.9982$, No.2:$R^2 = 0.9969$). When simultaneously detecting

with two kinds of primer / probe sets, accuracy of results could be provided with higher

reliability. It took only about 20 minutes per detection on the PCR1100 with using one step

RT-PCR reagent (THUNDERBIRD® Probe One-step qRT-PCR Kit). So, it could be to detect

10 copies of positive control RNA only in 20 minutes.

In CDC version, also, CDC No.1 and CDC No.2 could be detected with multichannel (Fig

2). Both No.1 and No.2 were detected in same sensibility, and possible to detect 10 copies

too. Furthermore, each Ct value (detected on the PCR1100) was depended on the rate of

dilution (No.1: R^2 = 0.9996, No.2: R^2 = 0.9983). As the same of NIID version, when

simultaneously detecting with two kinds of primer / probe sets, accuracy of results could be

provided with higher reliability. Furthermore, it took only about 13.5 minutes per detection

on the PCR1100 with using the same one step RT-PCR reagent, that was even faster

compared with NIID version. It could detect with at least10 copies of positive control RNA,

besides it took only in 13.5 minutes.

Detection of HCoV-229E in crude state

Crude sample of HCoV-229E was applied 10-fold serial dilution, afterwards without

treatment in advance and with one step RT-PCR reagent (THUNDERBIRD® Probe One-step

qRT-PCR Kit) was tested in the RT-PCR on the mobile real-time PCR device PCR1100. As

the result, without treatment for extraction, concentration and purification of RNA, it was

possible to detect HCoV-229E at least 8.9 x 10^2 $TCID_{50}$ / mL (Fig 3). Furthermore, each Ct

value (detected on the PCR1100) was depended on the rate of dilution, that is, virus titer (R^2

= 0.9949). Ct value might be relatively indicated to virus titer.

Also, it took only about 13 minutes per detection on the PCR1100 with using one step RT-

PCR reagent the same above of SARS-CoV-2. On another real-time PCR device using normal

two steps RT-PCR, it needed more than 90 minutes.

Therefore, it would be able to omit more than 135 minutes (60 minutes for RNA treatment,

75 minutes for RT-PCR) in total in detection of RNA virus compared with other current

methods.

DISCUSSION

Previously reported [10, 15, 16], with using the mobile real-time PCR device PCR1100, it

could be to detect unique strain rapidly, and sensibility and specificity are equivalent to other

devices. However, it would take 15 minutes at least to conclude RT-PCR for detection of unique

RNA in any case. Furthermore, it was necessary for RNA in advance to adjust with extraction,

concentration and purification.

First, this study addressed it to optimize each composition and PCR program according to

previously reported [7, 10], a part of which modified to quickly carry out RT-PCR for detection

of SARS-CoV-2 with using the mobile real-time PCR device PCR1100. With especially the

unit of reverse transcriptase enzyme decreased and the time of reverse transcription shorted,

sensibility of detection was improved (data not shown). Furthermore, as one step RT-PCR

reagent, THUNDERBIRD Probe One-step qRT-PCR Kit (TOYOBO) was used, of which was

possible and efficiently to carry out RT and probe' real-time PCR simultaneously. This time,

NIID and CDC version were selected for detection of SARS-CoV-2, both of which were unique

for N-gene of SARS-CoV-2 and used in general [7, 8, 9]. As a result, in the NIID version No.2,

CDC version No.1 and No.2, it was possible quantitatively to detect 10 copies or more of

positive control RNA with using mobile real-time PCR device PCR1100. However, in the NIID,

No.1 was able to detect only 100 copies or more, so No.2 was more sensitive than No.1 by 10

times. These results were about equal to previously reported [7, 10], that is, it might mean this

method to be right adequate to detect positive control RNA for SARS-CoV-2. Furthermore, in

both of CDC version by multichannel method, RT-PCR run could be finished in less than 14

minutes. That is, after RNA finished of extraction from each sample, this device would be

quickly able to discriminate presence of target. This faster RT-PCR might be caused by

combination of PCR1100 with RT-PCR reagent, of which was possible and efficiently to carry

out RT and PCR simultaneously. However, regretfully, in our situation unable to deal with

SARS-CoV-2, this method couldn't be demonstrated possible or not for genome RNA as

reported previously [7, 10]. Furthermore, primer / probe sets unique for gene of SARS-CoV-2

has been variously developed till now, so we would like to investigate about those sets if RT-

PCR is able to be faster to more in the PCR1100.

Second, we tried it to modify total system to detect SARS-CoV-2 easier. When treatment in

advance for RNA (mainly extraction, concentration and purification) it was required more than

60 minutes [12, 13, 17]. Therefore, in this study, we tried it to carry out RT-PCR without

treatment of RNA in advance, so that, direct RT-PCR. We tested for direct RT-PCR, in that

was used THUNDERBIRD® Probe One-step qRT-PCR Kit as one step RT-PCR reagent. With

above, this reagent was possible and efficiently to carry out RT and probe' real-time PCR

simultaneously, furthermore as reason, described possible to NAAT from crude samples [18].

Additionally, because of our situation unable to deal with SARS-CoV-2, therefore we

substituted HCoV-229E, low-risk for healthy, for SARS-2-CoV in direct RT-PCR this time. As

a result, surprisingly, without treatment for extraction, concentration and purification of RNA,

it was possible to detect HCoV-229E at least 8.9×10^2 $TCID_{50}$ / mL. Furthermore, Ct value

could be relatively to virus titer. This time, Lower Limit of Detection (LoD) couldn't show

accurately because failed to measure less than 8.9×10^2 $TCID_{50}$ / mL. However, as approximate

curve shown (y = -4.004x + 46.61), the LoD is supposed to less than 1 $TCID_{50}$ / mL. Also, it

took only about 13 minutes per detection on the PCR1100 with using one step RT-PCR reagent

the same above of SARS-CoV-2. Therefore, it would be able to omit more than 135 minutes

(60 minutes for RNA treatment, furthermore, 75 minutes for RT-PCR) in total in detection of

SARS-CoV-2 compared with other current methods. Already some reported direct RT-PCR for

SARS-CoV-2, it was necessary for especial reagent and additional treatment duration to direct

RT-PCR [12, 19, 20, 21, 22]. So, we could suggest novel method in this paper, in which used

PCR1100 device and commercial one step RT-PCR reagent only. However, our method must

be assessed in real SARS-CoV-2, further validated using clinical specimens, which contained

nasopharyngeal swabs and sputum. Furthermore, real-time RT-PCR reliable in saliva reported

[23, 24], its specimen must be assessed too. On the other hand, if low virus in air could be

collected, it might be able to detect quickly and easily on site by our novel method, and the

result be following prevent from droplet infection.

Although the other four community-acquired HCoVs (229E, OC43, HKU1, NL63) are a

common cause of common cold only, they are thought to cause pandemics and major outbreaks

of probably more severe respiratory diseases when they initially crossed species' barriers to

infect humans decades and centuries ago [3, 25]. That is, it would be possible new coronaviruses

to transfer again, therefore we are exposed to dangerous forever. On that time, the mobile real-

time PCR could be it save time compared to earlier detection methods. Furthermore, we think

that methods suggested in this paper should be suitable for various strains and it to be useful.

STUDY DESIGN

242 When each sample was assessed in the real-time RT-PCR, a ten-fold dilution series of each

243 was indicated with high relativity to Ct value on the mobile real-time PCR device PCR1100

244 ($R^2 = 0.99$).

ACKNOWLEDGEMENTS

247 We thank Dr. Kazuya Shirato and Dr. Tsutomu Kageyama at the National Institute of

248 Infections Disease in Japan (NIID) for positive control or technical comments, and Takashi

249 Fukuzawa in an ex-employee at Nippon Sheet Glass Co. Ltd. for technical comments or

250 experimental help.

AUTHOR CONTRIBUTIONS

253 M. Muraoka conceived, designed experiments, performed experiments, analysed the data and

254 wrote the manuscript. Y. Tanoi performed experiments and analysed the data. T. Tada wrote

255 the manuscript. M. Mizukoshi conceived and provided specimens. O. Kawaguchi conceived

256 and designed experiments. All authors also participated in the editorial process and approved

257 the manuscript.

ETHICAL STATEMENT

260 This study did not contain any studies involving human participants and animals performed

261 by any of the authors.

COMPETING INTERESTS

264 The authors declare that no competing interests exist. While M. Muraoka, T. Tanoi, T. Tada,

265 and O. Kawaguchi were employed at Nippon Sheet Glass at the time of this study, in where all

266 did not create a competing interest. Further, Nippon Sheet Glass had no involvement in this

267 study.

REFERENCES

[1] World Health Organization (WHO). WHO characterizes COVID-19 as a pandemic.

Rolling updates on coronavirus disease (COVID-19). Updated 11 March 2020.

Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-

2019/events-as-they-happen

[2] World Health Organization (WHO). 2019 Novel Coronavirus: Overview of the state of the

art and outline of key knowledge gaps/slides. Published 12 February 2020.

Available from: https://www.who.int/publications/m/item/2019-novel-coronavirus-

overview-of-the-state-of-the-art-and-outline-of-key-knowledge-gaps-slides

[3] Sin-Yee Fung, et al. A tug-of-war between severe acute respiratory syndrome coronavirus

2 and and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes

Infect., 2020; 9(1): 558-570.

doi: 10.1080/22221751.2020.1736644

[4] Puja Mehta, et al. COVID-19: consider cytokine storm syndromes and immunosuppression.

Lancet, 2020; 395(10229): 1033–1034.

doi: 10.1016/S0140-6736(20)30628-0

[5] Eskild Petersen, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.

Lancet Infect. Dis., 2020; 20(9): E238-E244.

doi: 10.1016/S1473-3099(20)30484-9

[6] Victor M Corman, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time

RT-PCR. Euro Surveill., 2020; 25(3): pii=2000045.

doi: 10.2807/1560-7917.ES.2020.25.3.2000045

[7] Kazuya Shirato, et al. Development of Genetic Diagnostic Methods for nCoV-2019 in

Japan. Jpn. J. Infect. Dis., 2020; 73(4).

doi: 10.7883/yoken.JJID.2020.061

[8] Centers for Disease Control and Prevention. 2019-Novel Coronavirus (2019-nCoV) Real-

time rRT-PCR Panel Primers and Probes. Updated 6 June 2020.

Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html

[9] Yu Jin Jung, et al. Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. bioRxiv [Preprint], Posted 27 February 2020.

doi: 10.1101/2020.02.25.964775

[10] Kazuya Shirato, et al. An ultra-rapid real-time RT-PCR method using the PCR1100 to detect Severe Acute Respiratory Syndrome Coronavirus-2. Jpn. J. Infect. Dis. [Advance Publication], Released 30 June 2020.

doi: 10.7883/yoken.JJID.2020.324

[11] World Health Organization (WHO). Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Published 19 March 2020.

Available from: https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117

[12] Soon Keong Wee, et al. Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler. Genes (Basel), 2020; 11(6): 664.

doi: 10.3390/genes11060664

[13] Leontine J R van Elden, et al. Frequent Detection of Human Coronaviruses in Clinical Specimens from Patients with Respiratory Tract Infection by Use of a Novel Real-Time Reverse-Transcriptase Polymerase Chain Reaction. J. Infect. Dis., 2004; 189(4): 652–657.

doi: 10.1086/381207

[14] Keykavous Parang, et al. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E). Molecules, 2020; 25(10): 2343.

doi: 10.3390/molecules25102343

[15] Kazuya Shirato, et al. Ultra-Rapid Real-Time RT-PCR Method for Detecting Middle East

Respiratory Syndrome Coronavirus Using a Mobile PCR Device, PCR1100. Jpn. J. Infect.

Dis., 2020; 73(3): 181-186.

doi: 10.7883/yoken.JJID.2019.400

[16] Kazuya Shirato, et al. An ultra-rapid real-time RT-PCR method for detecting human

orthopneumovirus using PCR1100. Jpn. J. Infect. Dis. [Advance Publication], Released 29

May 2020.

doi: 10.7883/yoken.JJID.2020.182

[17] Centers for Disease Control and Prevention. CDC Influenza SARS-CoV-2 (Flu SC2)

Multiplex Assay. Updated 9 July 2020.

Available from: https://www.fda.gov/media/139743/download

[18] TOYOBO Co. Ltd., Japan. TOYOBO Life Science Raw Material Catalog. Published 1

March 2019: p1.

Available from: http://www.bio-toyobo.cn/pdf/RawMaterialCatalog.pdf

[19] Emily A Bruce, et al. DIRECT RT-qPCR DETECTION OF SARS-CoV-2 RNA FROM

PATIENT NASOPHARYNGEAL SWABS WITHOUT AN RNA EXTRACTION STEP.

bioRxiv [Preprint], Posted 6 April 2020.

doi: 10.1101/2020.03.20.001008

[20] Licia Bordi, et al. Rapid and sensitive detection of SARS-CoV-2 RNA using the

SimplexaTM COVID-19 direct assay. J. Clin. Virol., 2020; 128: 104416.

doi: 10.1016/j.jcv.2020.104416

[21] Natacha Merindol, et al. SARS-CoV-2 detection by direct rRT-PCR without RNA

extraction. J. Clin. Virol., 2020; 128: 104423.

doi: 10.1016/j.jcv.2020.104423

[22] Mohammad Rubayet Hasan, et al. Detection of SARS-CoV-2 RNA by direct RT-qPCR

on nasopharyngeal specimens without extraction of viral RNA. PLoS One, 2020; 15(7):

e0236564.

doi: 10.1371/journal.pone.0236564

[23] Kelvin Kai-Wang To, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin.

Infect. Dis., 2020; 71(15): 841-843.

doi: 10.1093/cid/ciaa149

[24] Lorenzo Azzi, et al. Saliva is a reliable tool to detect SARS-CoV-2. J. Infect., 2020; 81(1):

e45-e50.

doi: 10.1016/j.jinf.2020.04.005

[25] Victor M. Corman, et al. Chapter Eight - Hosts and Sources of Endemic Human

Coronaviruses. Adv. Virus Res., 2018; 100: 163-188.

doi: 10.1016/bs.aivir.2018.01.001

     Table 1. Selected primers and probes for the real-time RT-PCR of SARS-CoV-2

            NIID and CDC, and HCoV–229E

target	primer/probe	Sequence	final conc.
N_Sarbeco (NIID No.1)	N_Sarbeco_F	5'-CAC ATT GGC ACC CGC AAT C-3'	0.40μM
	N_Sarbeco_R	5'-GAG GAA CGA GAA GAG GCT TG-3'	0.60μM
	N_Sarbeco_P	5'-FAM-ACT TCC TCA AGG AAC AAC ATT GCC A-BHQ-3'	0.20μM
NIID_2019-nCOV_N2 (NIID No.2)	NIID_2019-nCOV_N_F2	5'-AAA TTT TGG GGA CCA GGA AC-3'	0.40μM
	NIID_2019-nCOV_N_R2 ver3	5'-TGG CAC CTG TGT AGG TCA AC-3'	0.60μM
	NIID_2019-nCOV_N_P2	5'-Cy5-ATG TCG CGC ATT GGC ATG GA-BHQ-3'	0.20μM
2019-nCoV_N1 (CDC No.1)	2019-nCoV_N1-F	5'-GAC CCC AAA ATC AGC GAA AT-3'	0.20μM
	2019-nCoV_N1-R	5'-TCT GGT TAC TGC CAG TTG AAT CTG-3'	0.20μM
	2019-nCoV_N1-P	5'-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ-3'	0.20μM
2019-nCoV_N2 (CDC No.2)	2019-nCoV_N2-F	5'-TTA CAA ACA TTG GCC GCA AA-3'	0.40μM
	2019-nCoV_N2-R	5'-GCG CGA CAT TCC GAA GAA-3'	0.40μM
	2019-nCoV_N2-P	5'-HEX-ACA ATT TGC CCC CAG CGC TTC AG-BHQ-3'	0.20μM
HCoV-229E_N	HCoV-229E_NF	5'-CAG TCA AAT GGG CTG ATG CA-3'	0.30μM
	HCoV-229E_NR	5'-AAA GGG CTA TAA AGA GAR* TAA GGT ATT CT-3'	0.30μM
	HCoV-229E_NP	5'-FAM-CY**C TGA CGA CCA CGT TGT GGT TCA-BHQ-3'	0.20μM

*R= A or G, **Y= C or T

Probe: N_Sarbeco_P was attached with 6-carboxyfluorescein (FAM) at the 5' end, probe:

NIID_2019-nCOV_N_P2 with cyan 5 (Cy5), probe: 2019-nCoV_N1-P with FAM, probe:

2019-nCoV_N1-P with HEX, and probe: HCoV-229E_NP with FAM. ALL probes were

attached with Black Hole Quencher (BHQ, Biosearch Technologies, Inc., USA) at the 3'

end. As above, NIID version or CDC version could be used with multichannel.

Table 2. Sequences of positive RNA control for the real-time RT-PCR of SARS-

CoV-2 of CDC version.

2019-nCoV_N1	ACA AAC UAA AAU GUC UGA UAA UGG ACC CCA AAA UCA GCG AAA UGC ACC CCG CAU UAC GUU UGG UGG ACC CUC AGA UUC AAC UGG CAG UAA CCA GAA UGG AGA ACG CAG UGG GGC GCG AUC
2019-nCoV_N2	CUA AUC AGA CAA GGA ACU GAU UAC AAA CAU UGG CCG CAA A UU GCA CAA UUU GCC CCC AGC GCU UCA GCG UUC UUC GGA AUG UCG CGC AUU GGC AUG GAA GUC ACA CCU UC

Fig 1. Correlation of copies number and Ct value when detection of positive control

for NIID version on the PCR1100.

412   **Fig 2. Correlation of copies number and Ct value when detection of positive control**

413   **for CDC version on the PCR1100. The top is CDC version No.1 (2019-**

414   **nCoV_N1), the bottom is No.2 (2019-nCoV_N2).**

Fig 3. Correlation of virus titer and Ct value when detection of HCoV-229E on the

PCR1100.

20